To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
Summary
HB1463 would bar the use of any federal funds to implement, administer, or enforce the Food and Drug Administration’s final rule on “Medical Devices; Laboratory Developed Tests,” including any substantially similar rule. The bill specifically targets the FDA rule submitted for publication in the Federal Register on May 6, 2024, and would prevent the agency from using appropriated funds to carry out that regulatory framework.
In practical terms, the bill would block federal enforcement of the FDA’s laboratory-developed tests rule, which is intended to regulate certain diagnostic tests developed and used within laboratories as medical devices. By cutting off funding for implementation and enforcement, the bill would effectively preserve the status quo for laboratories and related health-care providers unless a different legal or regulatory approach is adopted.
Impact
The bill would not directly amend the Food, Drug, and Cosmetic Act, but it would restrict how federal funds may be used by the FDA with respect to the laboratory-developed tests final rule. If enacted, it would prevent the agency from enforcing the rule and could limit regulatory oversight of laboratory-developed diagnostic tests nationwide. The measure would affect the FDA, clinical laboratories, diagnostic test developers, and potentially patients and health systems that rely on laboratory testing.
Sentiment
Based on the bill’s sponsorship and the absence of recorded committee debate or votes in the provided materials, the available sentiment appears supportive among the bill’s sponsors and neutral-to-unclear overall. The bill was introduced by Representative Finstad with Representative Crenshaw and referred to the House Committee on Energy and Commerce, suggesting it is at an early stage without a documented public vote or committee disposition in the record provided.
Contention
The central point of contention is the FDA’s authority to regulate laboratory-developed tests as medical devices and whether that rule should be implemented at all. Supporters of the bill are likely concerned that the FDA rule would impose burdens on laboratories, slow access to testing, or duplicate existing oversight, while opponents would likely argue that the rule is needed to ensure test quality, safety, and consistency. No specific committee arguments or recorded votes were provided, so the dispute is inferred from the bill’s target and structure.